Jul 2020

ANTG’S EVE CANNABIS PRODUCT USED IN STUDY TO INVESTIGATE THE POTENTIAL INHIBITION OF CANCER CELLS WITHOUT IMPACTING NORMAL CELLS

In an interview with the Hunter Medical Research Institute (HMRI), Dr Matt Dun, an Australian biomedical scientist and cancer researcher discusses his three-year investigation into ANTG’s high-CBD proprietary strain Eve and his recent paper reviewing the health benefits, side-effects and anti-cancer potential of THC and CBD.

“ANTG wanted me to test (Eve) against cancer, so we initially used Leukaemia cells and were really surprised by how sensitive they were. At the same time, the cannabis didn’t kill normal bone marrow cells, nor normal healthy neutrophils [white blood cells].” Dr Matt Dun

Read more here

ANTG appoints new Business Operations Manager   Australian Natural Therapeutics […]

READ MORE >

ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).

READ MORE >

In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.

READ MORE >

We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.

LEARN ABOUT ANTG HERE >